Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Mucositis 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × kang-lai-te × Clear all
NCT03101514 2021-06-23

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

First Affiliated Hospital of Harbin Medical University

Phase 2 Completed
53 enrolled 11 charts
Head & NeckOther

Head and Neck Neoplasms, Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡